Tampa, Fla. "The MKO Melt is a really great and simple way to have
fewer IVs and less of an anesthesia presence. And it's more titratable
than giving valium."
Omidria
Omidria (phenyle-
phrine and ketorolac
intraocular solution)
1% / 0.3%, the
injectable that helps
maintain pupillary
dilation intraoperative-
ly, is now once again
separately payable.
The drug enjoyed 3
years of "pass-
through" status, mean-
ing that the cost was
fully refunded in hos-
pitals and refunded
80% in ASCs, but
Omidria lost its pass-
through effective Jan.
1, 2018. This spring,
though, Congress
voted to give the drug
2 more years of pass-
through status.
Following a 9-month
N O V E M B E R 2 0 1 8 • O U T PA T I E N T S U R G E R Y. N E T • 7 9
• STEADY Omidria, which maintains pupil size by preventing intraoperative miosis (pupil
constriction) and reduces post-op ocular pain, is the only NSAID-containing product FDA-
approved for intraocular use.
• PREAPPROVED Patients with a green stamp next to their name on the schedule are
"preapproved" for Omidria.
Anna
Risdorfer,
RN
Omeros
